Loading...
•
Sep 30, 2023
Third Harmonic Q3 2023 Earnings Report
Announced financial results for the third quarter ended September 30, 2023.
Key Takeaways
Third Harmonic Bio reported a net loss of $7.3 million for the third quarter of 2023, with cash and cash equivalents totaling $273.9 million as of September 30, 2023. The company is on track to file a U.S. IND application for THB335 and initiate clinical studies in 1H'24.
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24.
Cash and cash equivalents totaled $273.9 million as of September 30, 2023.
Research and development (R&D) expenses increased to $6.0 million for the three months ended September 30, 2023.
Net loss for the three months ended September 30, 2023 decreased to $7.3 million.
Forward Guidance
Third Harmonic Bio believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...